-+ 0.00%
-+ 0.00%
-+ 0.00%

BioSapien targets mid-2026 start for Phase I cancer implant trial in Abu Dhabi

PUBT·08/10/2026 06:21:36
Listen to the news
BioSapien targets mid-2026 start for Phase I cancer implant trial in Abu Dhabi
  • Hub71 portfolio company BioSapien secured AED 27.5 million (USD 7.5 million) funding led by Global Ventures.
  • BioSapien plans a Phase I clinical trial in Abu Dhabi by mid-2026 for its MediChip chemotherapy implant.
  • Regulatory clearances covered DoH for an IND submission, EDE for clinical trials, and an IRB review.
  • BioSapien aims to run future Phase I trials from the UAE, positioning the approval pathway as repeatable.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hub71 Ltd published the original content used to generate this news brief on August 10, 2026, and is solely responsible for the information contained therein.